Drug intelligence / Profile preview

HD-001

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules

Overview

**HD-001** is a small molecule protein kinase inhibitor developed by Horizon Discovery (now part of Revvity) in collaboration with AstraZeneca for oncology applications. It targets a novel kinase mutated in cancers such as colon and lung, with particular relevance to K-Ras mutant tumors, which occur in up to 40% of cancers and drive resistance to targeted therapies. The program, in early drug discovery stages as of its announcement, aimed to address the unmet need in K-Ras-driven malignancies associated with poor outcomes.[5][11]

Beyond the preview

Go deeper on HD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD-001.

Explore the full profile